Take a look at the evolution of aspirin used in modern disease prevention to gain perspective on how more recent developments may affect your practice.
Daily Dose: Waist-to-Hip Ratio Better Predictor for Mortality than BMI?
Your daily dose of the clinical news you may have missed.
Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care
Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.
Adding 3000 Ordinary Steps/Day Reduced BP in Sedentary Older Adults with Hypertension
An e-health lifestyle walking intervention partially supported by remote coaching led to significant improvement in BP in older adults as well as a desire to keep walking.
Primary Viewpoints Episode 4: Lp(a): The Next CVD Target?
Patrick Moriarty, MD, from the University of Kansas Medical Center, discusses the role of Lp(a) as a risk factor for cardiovascular disease and the phase 3 trials of a potential treatment.
GLP-1 Mimetics, SGLT-2 Inhibitors Understudied in Black Populations in Pivotal Trials, Benefits Questioned
Pivotal cardiovascular outcome trials that evaluated cardiorenal benefits of the newer classes were not designed to consider racial/ethnic variations, researchers state.
Biosimilar Liraglutide Noninferior to Reference Product in Persons with Type 2 Diabetes: Phase 3 Trial
The biosimilar to the GLP-1 mimetic Victoza proved noninferior for reduction of HbA1c and had similar positive effects on body weight, lipids, and blood pressure.